Key Highlights

  • NeuroSense Therapeutics shares fell 17% to $0.33.
  • The company will implement a 1-for-20 reverse share split.
  • Post-split Nasdaq trading is expected to begin September 14, 2026.
  • Issued and outstanding ordinary shares will be reduced from about 37.9 million to 1.9 million.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares fell 17% to $0.33 after the company announced it will implement a 1-for-20 reverse share split, with post-split Nasdaq trading expected to begin September 14, 2026.

What Happened

The split will reduce issued and outstanding ordinary shares from about 37.9 million to 1.9 million, while leaving authorized Share Capital unchanged and proportionately adjusting warrants and options.

Market Reaction

Shares fell as investors responded to the reverse split announcement, a pattern common among stocks undertaking share-count adjustments ahead of the effective date.

Outlook

The transition to post-split trading beginning September 14, 2026, represents the next relevant development for NeuroSense Therapeutics shareholders.